FindTrial
Sign In

carboplatin chemotherapy

DRUG2 trials

Sponsors

Calithera Biosciences, Inc, University of Utah

Conditions

KEAP1 Gene MutationNFE2L2 Gene MutationNRF2 Gene MutationNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-Squamous Non-Small Cell Neoplasm of LungNon-squamous Non-small-cell Lung Cancer

Phase 1

Tumor Treating Fields for Locally Advanced NSCLC
RecruitingNCT06124118
University of UtahNon Small Cell Lung Cancer
Start: 2024-04-04End: 2027-11-15Target: 30Updated: 2026-01-08

Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
TerminatedNCT04265534
Calithera Biosciences, IncKEAP1 Gene Mutation, NFE2L2 Gene Mutation, Non-Small Cell Lung Cancer +3
Start: 2020-07-24End: 2022-02-09Updated: 2022-09-21

Related Papers

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.
2024-10-2728 citations
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
Journal of Clinical Oncology2020-05-206 citations